Biogen's Response to Charities' Letter
23 May 2018
On 16th May, the SMA charities wrote to leading managers of Biogen about the Scottish Medicines Consortium’s decision that due to pricing, nusinersen may only be accessed by those with SMA Type 1. We are urging Biogen to continue their firm commitment to the SMA community, review their pricing and resubmit their application with the aim of access being extended to those with SMA Types 2 and 3.
Biogen have provided a response which you can read here.